HK1216253A1 - 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物 - Google Patents
新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物Info
- Publication number
- HK1216253A1 HK1216253A1 HK16104238.6A HK16104238A HK1216253A1 HK 1216253 A1 HK1216253 A1 HK 1216253A1 HK 16104238 A HK16104238 A HK 16104238A HK 1216253 A1 HK1216253 A1 HK 1216253A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prevention
- pharmaceutically acceptable
- treatment
- pharmaceutical composition
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120146081 | 2012-12-14 | ||
PCT/KR2013/011668 WO2014092514A1 (ko) | 2012-12-14 | 2013-12-16 | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1216253A1 true HK1216253A1 (zh) | 2016-10-28 |
Family
ID=51732919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16104238.6A HK1216253A1 (zh) | 2012-12-14 | 2016-04-13 | 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9790197B2 (zh) |
EP (2) | EP3882244A1 (zh) |
JP (1) | JP6293168B2 (zh) |
KR (1) | KR101630243B1 (zh) |
CN (1) | CN105121433B (zh) |
ES (1) | ES2863985T3 (zh) |
HK (1) | HK1216253A1 (zh) |
WO (1) | WO2014092514A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112062693A (zh) * | 2020-09-23 | 2020-12-11 | 上海吉奉生物科技有限公司 | 一种2-(9h-芴-9-甲氧基羰基氨基)-3-甲基-2-丁烯酸的合成方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH583723A5 (zh) | 1972-12-18 | 1977-01-14 | Hoechst Ag | |
GB1425295A (en) | 1974-01-23 | 1976-02-18 | Rizh Politekhn I | Alpha-aminoylidenephthalides and processes for their preparation |
FR2392951A2 (fr) | 1975-02-07 | 1978-12-29 | Creat Lab | Nouveaux derives de la ninhydrine, leurs procedes de preparation et medicaments contenant ces derives |
GB1533388A (en) | 1975-02-07 | 1978-11-22 | Creat | Ninhydrin-phenol condensation products their preparation and use as therapeutic agents |
US3984552A (en) | 1975-02-24 | 1976-10-05 | Merck & Co., Inc. | 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids |
GB8327598D0 (en) | 1983-10-14 | 1983-11-16 | Akzo Nv | Pharmacologically active diarylindane-13-diones |
SE8902274D0 (sv) | 1989-06-22 | 1989-06-22 | Univ Cincinnati | Indenoidole compounds ii |
JO1676B1 (en) | 1990-10-16 | 1992-08-09 | جامعة باث | Extra compounds indinol II |
DE4035809A1 (de) * | 1990-11-10 | 1992-05-14 | Boehringer Mannheim Gmbh | Verwendung von thiazoloisoindolinon-derivaten als antivirale arzneimittel |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
ES2228370T3 (es) | 1999-08-30 | 2005-04-16 | Maruishi Pharmaceutical Co., Ltd. | Compuestos de 1,4-dihidro-4-oxoquinolina 1,2-disustituidos. |
JP2001089455A (ja) | 1999-09-17 | 2001-04-03 | Maruishi Pharmaceutical Co Ltd | 5,10−ジヒドロ−11H−インデノ〔1,2−b〕キノリン−10−オン誘導体 |
US7371168B2 (en) | 2001-10-05 | 2008-05-13 | Igt | Gaming apparatus and method of gaming including interactive gaming symbols for producing different outcomes |
WO2003082265A2 (en) * | 2002-04-02 | 2003-10-09 | Fujisawa Pharmaceutical Co | Pharmaceutical composition for treating or preventing virus infectious diseases |
WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
EP1569928A4 (en) | 2002-11-08 | 2008-12-10 | Government Of The State Of Sar | THERAPEUTIC COMPOUNDS AND METHOD |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | HEPARAN SULFATE INHIBITORS |
US20100261706A1 (en) | 2008-12-08 | 2010-10-14 | Inotek Pharmaceuticals Corporation | Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof |
EP2324820B1 (en) | 2009-11-04 | 2016-03-02 | Inopharm Limited | Stable fluindione composition comprising one or more antioxidant agents |
EP2722322B8 (en) * | 2011-06-16 | 2020-03-11 | Korea Research Institute of Chemical Technology | 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient |
CA3124852A1 (en) * | 2011-06-16 | 2012-12-20 | Korea Research Institute Of Chemical Technology | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases |
-
2013
- 2013-12-16 US US14/651,656 patent/US9790197B2/en active Active
- 2013-12-16 EP EP21152125.7A patent/EP3882244A1/en active Pending
- 2013-12-16 KR KR1020130156409A patent/KR101630243B1/ko active IP Right Grant
- 2013-12-16 ES ES13862055T patent/ES2863985T3/es active Active
- 2013-12-16 WO PCT/KR2013/011668 patent/WO2014092514A1/ko active Application Filing
- 2013-12-16 CN CN201380073105.3A patent/CN105121433B/zh active Active
- 2013-12-16 JP JP2015547863A patent/JP6293168B2/ja active Active
- 2013-12-16 EP EP13862055.4A patent/EP2933254B1/en active Active
-
2016
- 2016-04-13 HK HK16104238.6A patent/HK1216253A1/zh unknown
-
2017
- 2017-02-15 US US15/433,536 patent/US9951058B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2863985T3 (es) | 2021-10-13 |
EP2933254A1 (en) | 2015-10-21 |
US9790197B2 (en) | 2017-10-17 |
US9951058B2 (en) | 2018-04-24 |
JP2016504321A (ja) | 2016-02-12 |
US20150336920A1 (en) | 2015-11-26 |
CN105121433B (zh) | 2018-01-23 |
EP2933254B1 (en) | 2021-01-20 |
EP2933254A4 (en) | 2016-05-11 |
KR20140081687A (ko) | 2014-07-01 |
JP6293168B2 (ja) | 2018-03-14 |
KR101630243B1 (ko) | 2016-06-15 |
WO2014092514A1 (ko) | 2014-06-19 |
EP3882244A1 (en) | 2021-09-22 |
CN105121433A (zh) | 2015-12-02 |
US20170158684A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551089A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
HK1250714A1 (zh) | 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物 | |
EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
IN2014KN00948A (zh) | ||
EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
EP2722042A4 (en) | INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | |
EP2823819A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING OLEANOLIC ACID ACETATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MEDIATED DISEASE BY TLR OR IL-6 | |
WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
EP3138834A4 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin | |
EP2687216A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES ASSOCIATED WITH AGING, CONTAINING AS AN ACTIVE INGREDIENT PROGERIN EXPRESSION INHIBITOR, AND SCREENING METHOD FOR SEARCHING FOR PROGERIN EXPRESSION INHIBITOR | |
EP2871187A4 (en) | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | |
SI2722322T1 (sl) | 1,3-di-okso-indenski derivat, farmacevtsko sprejemljiva sol ali optični izomer le-tega, postopek njegov priprave in farmacevtski sestavek, ki ga vsebuje kot protivirusno aktivno sestavino | |
WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
EP2886112A4 (en) | COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME | |
HK1216253A1 (zh) | 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物 | |
EP2862573A4 (en) | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF VASER SPERMABILITY-RELATED DISEASES WITH IMATINIB OR PHARMACEUTICAL ACCEPTABLE SALT AS AN ACTIVE SUBSTANCE | |
IN2014DN10683A (zh) | ||
HK1251988A1 (zh) | 包含作為活性成分的色甘酸或其藥學上可接受的鹽的用於預防和治療肝臟疾病的藥物組合物 | |
EP2617702A4 (en) | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR THE PREPARATION OF THE NEW BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING COMPLICATIONS OF DIABETES | |
ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
PT3611158T (pt) | Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral |